Vital Signs with Jacob Effron and Nikhil Krishnan

Dr. Andy Beck, PathAI CEO, discusses AI adoption in diagnosis, nailing go-to-market strategy, digitalizing pathology labs, regulatory frameworks, standardizing diagnoses, the future of pathologists' jobs, working in Daphne Koller's lab, and the potential of AI in drug development and healthcare.

Jacob and Nikhil sit down with Dr. Austin Chiang, an interventional GI doc and Chief Medical Officer of Medtronic’s GI business who also has >500K TikTok Followers. We discuss how social media companies deal with public health issues, how doctors can use social media, lessons from being a “physician influencer,” the consumerization of GLP-1s and more. 0:00 intro1:02 how Austin got into medicine and social media4:59 highlights and lowlights of being a recognizable figure in the medical world8:47 balancing engagement with education25:22 how to steer away from misinformation30:51 the consumerization of GLP-1s39:24 tips for doctors on social media45:45 how to market to physicians47:31 public health campaigns on social media 52:10 Austin’s favorite post

Jacob and Nikhil sit down with Dotmatics CEO Thomas Swalla to discuss R&D software, differences in software requirements across biotechs, growing through 11 acquisitions and expanding beyond life sciences.  0:00 intro0:36 getting into healthcare5:20 what R&D looks like today8:03 what does Dotmatics do?13:06 differences in software requirements across biotechs20:15 bundling vs. “best-of-breed”23:46 do life sciences need their own data tools?26:44 incorporating AI into Dotmatics tools34:38 AI replacing scientists37:39 how Dotmatics tools can serve companies outside of life sciences39:50 acquisition strategy44:43 spaces for innovation in R&D

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech. 00:00 intro00:59 Daphne’s journey09:02 AI and biology discovery10:42 insitro vs. traditional pharma19:47 phenotyping patients25:44 early mistakes29:34 the future of data35:16 partnering with larger pharma companies38:00 impact of LLMs on biopharma43:47 over-hyped/under-hyped

00:00 intro01:08 James’ background04:39 regulation of AI medical devices14:43 impact of foundation models on healthcare19:41 the future of cancer detection23:47 real-world control arms35:18 AI drift37:42 over-hyped/under-hyped40:03 most surprising AI interaction 

Jacob and Nikhil sit down with Dr. Ezekiel Emanuel and discuss his reflections on his “Why I want to Die at 75” piece, how publishing/financial incentives harm research, doctors' increasing social isolation and his love of chocolate-making.

Jacob sits down with HumanFirst CEO Andy Coravos and Orchestra CEO Ashoka Rajendra to discuss at home data collection in trials, Andy being an EIR at the FDA, why Benchling has been so successful and more.

Andy Slavitt, former Optum EVP, head of CMS, COVID advisor and healthcare.gov saver joins Nikhil and Jacob to discuss public/private sector collaboration, Optum’s evolution, and his lessons on communication from COVID. Andy also shared his career journey, what he would do if he was running United today and how the private sector can work better with the public sector.

Jacob and Nikhil sit down with Mike Kopko, CEO and co-founder of Pearl Health to discuss Pearl’s care model and what it’s been like building the company as ACO Reach evolved. Mike also shares some great stories negotiating claims in the early days of Oscar.

Jacob and Nikhil sit down with Dr. Jeffrey Kang, CEO of WellBe Senior Medical, and former President of ChenMed, SVP Health and Wellness Solutions at Walgreens, CMO at Cigna, CMO at CMS and CEO of Urban Medical Group. They discuss risk adjustment, retailers in healthcare and how healthcare has/hasn't changed since his work doing risk-based care for complex patients and at CMS in the 80s and 90s.